GENE ONLINE|News &
Opinion
Blog

2019-12-30| Technology

‘CRISPR Babies’ Researchers Given Prison Sentence by Chinese Court

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K. Gopinath, Ph.D.

In November 2018, Chinese biophysicist He Jiankui shocked the world by announcing his creation of the “CRISPR babies” at an International Summit causing much furor across the globe. The researchers claimed that the intention of the study was to immunize the twin baby sisters Lulu and Nana against HIV by modifying the CCR5 gene in the embryo. However, a recent examination of the unpublished manuscripts by the MIT Technology Review involving four experts have found that the claims made by He and his team are not supported by data.

According to a report from Xinhua news agency, on December 30th, the Shenzhen Nanshan District People’s Court in South China has punished He and his coworkers Zhang Renli and Qin Jinzhou. The defendants were found to be guilty of jointly carrying out human embryo gene editing and reproductive medical activities for reproductive purposes. The court has found that the trio conspired since 2016 and has deliberately violated scientific regulations and crossed ethical boundaries.

While He Jiankui is sentenced to a three-year prison sentence including a fine of 3 million Chinese yuan (US$430,000), the others are given lesser sentences. Zhang Renli was sentenced to two years with a 1 million yuan fine and Qin Jinzhou received an 18-month sentence with a 500,000 yuan fine. All defendants pleaded guilty to the offense.

 

References
  1. https://mp.weixin.qq.com/s/5utIos-cXONVUh7Qn0Za9w
  2. https://www.technologyreview.com/s/614764/chinas-crispr-babies-read-exclusive-excerpts-he-jiankui-paper/

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Groundbreaking CRISPR/Cas9-based Genome Editing Therapy Secured the Second FDA Approval
2024-01-18
R&D
Study Finds High Viral Loads Fuel Higher HIV Recombination Rates
2024-01-12
GeneOnline’s Pick: Top 10 Global Biotech News Stories in 2023
2023-12-27
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top